Anastrozole vs. tamoxifen for early breast cancer
Part of Bones, joints & muscles, Cancer, Pain, Skin clinical trials.
This trial compares two hormone therapies, anastrozole and tamoxifen, for treating early breast cancer. It aims to see which one works better to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 59 and 70.
- You have early breast cancer that is hormone receptor positive (both estrogen and progesterone receptors).
- You have not used androgen suppression therapy along with radiation for prostate cancer.
- You are willing to provide bone density data if available.
- You have not received a dose change of the study drug during this treatment course.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
This trial is testing two low-dose hormone therapies (exemestane and tamoxifen) to see which works better for preventing breast cancer in postmenopausal women who are at high risk. It's a double-blind study, so neither you nor your doctor will know which drug you're taking.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.